Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating reiterated by investment analysts at Maxim Group in a research note issued on Thursday. They presently have a $15.50 price target on the stock. Maxim Group’s price target would indicate a potential downside of 15.51% from the company’s current price.

TEVA has been the topic of a number of other research reports. Vetr lowered Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating and set a $32.27 target price on the stock. in a research report on Tuesday, July 4th. BidaskClub upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research report on Wednesday, July 5th. Wells Fargo & Company reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, June 27th. Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research report on Thursday, June 22nd. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $33.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Friday, June 23rd. Five research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $31.42.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 2.73% during trading on Thursday, reaching $18.34. 18,304,552 shares of the company’s stock traded hands. The company has a 50 day moving average price of $20.22 and a 200-day moving average price of $28.82. The stock’s market cap is $18.64 billion. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $52.66.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the prior year, the company posted $1.25 EPS. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Earns “Hold” Rating from Maxim Group” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/09/14/teva-pharmaceutical-industries-limited-teva-earns-hold-rating-from-maxim-group.html.

Several large investors have recently modified their holdings of TEVA. Advisors Asset Management Inc. increased its position in shares of Teva Pharmaceutical Industries Limited by 2.7% during the 1st quarter. Advisors Asset Management Inc. now owns 24,294 shares of the company’s stock worth $780,000 after purchasing an additional 643 shares during the last quarter. Comerica Bank increased its position in shares of Teva Pharmaceutical Industries Limited by 21.3% during the 1st quarter. Comerica Bank now owns 102,913 shares of the company’s stock worth $3,265,000 after purchasing an additional 18,092 shares during the last quarter. British Columbia Investment Management Corp increased its position in shares of Teva Pharmaceutical Industries Limited by 8.1% during the 1st quarter. British Columbia Investment Management Corp now owns 111,905 shares of the company’s stock worth $3,591,000 after purchasing an additional 8,400 shares during the last quarter. Karp Capital Management Corp acquired a new stake in shares of Teva Pharmaceutical Industries Limited during the 1st quarter worth about $5,625,000. Finally, Paragon Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 47.2% during the 1st quarter. Paragon Capital Management LLC now owns 233,842 shares of the company’s stock worth $7,503,000 after purchasing an additional 74,938 shares during the last quarter. 56.87% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.